1 1 9 5 a r t i c l e s Obesity and its associated morbidities pose a growing threat to public health 1 . However, the prospects for their pharmacological treatment remain bleak 2 . Thus, identification of molecular pathways that can be effectively and safely targeted for therapy has acquired new urgency. A rational approach involves exploration of signaling mechanisms that elicit satiety, such as those activated by insulin and leptin in hypothalamic neurons 3, 4 , with the goal of identifying tractable candidates for therapeutic intervention.
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But, owing to Cpe's pleiotropic actions, the mechanisms linking loss of Cpe function with the complicated metabolic phenotype of Cpe fat mice are unclear 26, 28, 29 .
In this study, we provide genetic evidence of a key role of the FoxO1-Cpe regulatory axis in the integration of food intake and energy expenditure.
RESULTS

Somatic deletion of FoxO1 in Pomc neurons
In view of the role of FoxO1 in hypothalamic neuropeptide signaling 8, 9 , and of lingering uncertainties as to its primary target genes in this cell type 9 , we generated Pomc-Foxo1 −/− mice. Four lines of evidence documented somatic deletion of the gene: mating of Gt(ROSA)26Sor tm2Sho (Rosa-Gfp) reporter mice with transgenic mice expressing Cre under control of the Pomc promoter 30 resulted in GFP immunoreactivity that largely overlapped with endogenous Pomc expression patterns ( Supplementary Fig. 1a) ; allele-specific PCR showed Foxo1 recombination in the pituitary, where ~40% of cells express Pomc, but not in other brain regions or peripheral tissues ( Supplementary Fig. 1b) ; pituitary Foxo1 messenger RNA expression was ~40% lower in Pomc-Foxo1 −/− mice ( Supplementary Fig. 1c) ; and chromatin immunoprecipitation (ChIP) from mediobasal hypothalami showed FoxO1 bound to the Pomc promoter 9 in wild-type (WT), but not in Pomc-Foxo1 −/− , mice (Supplementary Fig. 1d ).
Pomc-Foxo1 −/− mice were born at mendelian frequency with normal appearance. Their basal and stress-induced serum corticosterone, as well as pituitary Pomc levels, were comparable to those in WT mice ( Supplementary Fig. 1e,f) , demonstrating that FoxO1 ablation does not affect corticotroph function 31 .
Body weight and energy balance in Pomc-Foxo1 −/− mice Body weights of Pomc-Foxo1 −/− mice were similar to WT littermates until ~6 weeks of age, but became ~15% lower thereafter (Fig. 1b,c) . Reduced body weight was associated with lower body mass index, despite shorter nasoanal length ( Supplementary Fig. 2a-d) , indicating that it is not solely an effect of the smaller body size of the mutant mice. The change in body weight was accounted for by a ~27% lower fat content (Fig. 1d,e) and was associated with a relative (in terms of percentage), but not absolute (in terms of grams per mouse), higher amount of lean mass (Fig. 1f,g ), as seen in a previous study of leptin receptor-mutant mice 32 .
To evaluate the leanness of Pomc-Foxo1 −/− mice, we measured food intake and energy expenditure. Cumulative ad libitum food intake was significantly lower in mutant mice (Fig. 2a,b) , more so in females when normalized by lean mass (Fig. 2c,d ). In contrast, energy expenditure ( Supplementary Fig. 3a,b) , locomotor activity ( Supplementary Fig. 3c ) and respiratory quotient ( Supplementary  Fig. 3d ) were unchanged. The decrease in food intake was independent of changes in circadian feeding patterns ( Supplementary  Fig. 3e ). Insulin and glucose levels in the fasting, fed and refed states, as well as insulin sensitivity and tolerance to a glucose load, were also normal (data not shown).
To characterize the hypophagia of Pomc-Foxo1 −/− mice, we measured food intake after an 18-h fast. Mutant mice showed an ~18% decrease in 'rebound' food intake compared to WT littermates, both in absolute values (Fig. 2e) and when corrected for body weight (Fig. 2f) . These data indicate that the leanness of Pomc-Foxo1 −/− mice results from an unusual dissociation of hypophagia from reduced energy expenditure 33 .
Given the interaction between insulin and FoxO1 and leptin and signal transducer and activator of transcription-3 signaling 9 , we tested leptin sensitivity in Pomc-Foxo1 −/− mice. Leptin curtailed food intake more markedly in Pomc-Foxo1 −/− mice than in WT mice (Fig. 2g) , consistent with increased leptin sensitivity. Unexpectedly, PomcFoxo1 −/− mice showed a near doubling of leptin levels in all conditions tested (Fig. 2h) .
Regulation of Pomc expression in Pomc-Foxo1 −/− mice To rule out developmental abnormalities associated with FoxO1 ablation, we counted Pomc-and Npy and Agrp-expressing neurons in the mediobasal hypothalamus. We did not detect differences in Pomc and Npy neuron number in 4-week-old mice (data not shown). In adult Pomc-Foxo1 −/− mice, we found a ~20% reduction in the number of Pomc neurons (not a significant difference) and no difference in Npy/ Agrp neurons (Supplementary Fig. 4a ). On the basis of these data, we normalized measurements of Pomc and Agrp mRNA and peptide by the average number of relevant neurons. (We show absolute values in Supplementary Fig. 4b,c To test whether hypophagia and leanness result from changes in hypothalamic neuropeptide mRNA, we measured mediobasal hypothalamus Pomc expression. We detected a significant increase Fig. 5a,b) . Agrp mRNA expression was similar between the two groups under both conditions (data not shown). But, in adult Pomc-Foxo1 −/− mice, Pomc levels did not differ from controls under either condition ( Supplementary Fig. 5c,d ). This finding is consistent with previous data that FoxO1 gain-of-function fails to affect Pomc in the arcuate nucleus of adult mice 9 . In both ad libitum-fed and refed PomcFoxo1 −/− mice, we detected a decrease of Agrp mRNA ( Supplementary  Fig. 5c,d ) that significantly lowered the Agrp/Pomc ratio (P < 0.05) ( Supplementary Fig. 5e,f) , potentially resulting in an anorexigenic behavior. However, the data indicate that the observed changes in food intake cannot be accounted for by increased Pomc expression.
FoxO1 inactivation affects hypothalamic Pomc processing
We next measured mediobasal hypothalamus content of Pomc peptide, its processing intermediates and cleavage products. The levels of full-length Pomc and Pomc-derived neuropeptides in the mediobasal hypothalamus were comparable in ad libitum-fed Pomc-Foxo1 −/− and WT mice (data not shown). Likewise, amounts of Pomc and its initial cleavage product adrenocorticotrophic hormone (Acth) were unaltered in Pomc-Foxo1 −/− mice compared to WT mice after 6 h of refeeding (Table 1) . However, the abundance of the anorexigenic peptide α-Msh was significantly increased, and the level of total β-endorphin was up slightly after refeeding ( Table 1) . Agrp protein expression trended downward in ad libitum-fed mice (data not shown) and decreased significantly in refed Pomc-Foxo1 −/− mice, resulting in reduced hypothalamic Agrp/α-Msh ratio ( Table 1) . These data indicate that FoxO1 ablation increases Pomc processing into α-Msh, its anorexigenic product. The prohormone processing enzymes Pc-2 and Cpe cleave Acth and β-lipotropin in the arcuate nucleus (containing hypothalamic Pomc neurons) and paraventricular nucleus (containing projections and primary target neurons of arcuate nucleus Pomc neurons) into α-Msh and β-endorphin 13, 14 . The observed neuropeptide patterns are consistent with increased expression of Cpe, Pc-2 or both in the hypothalamus of PomcFoxo1 −/− mice 34, 35 . But Pcsk2 mRNA expression was unaltered in whole mediobasal hypothalamus ( Supplementary Fig. 6a ), arcuate nucleus and paraventricular nucleus (data not shown), as was the active 64-to 66-kDa Pc-2 peptide in mediobasal hypothalamus of refed Pomc-Foxo1 −/− mice ( Supplementary Fig. 6b ).
These observations led us to predict that hypothalamic Cpe mRNA expression should be higher in Pomc-Foxo1 −/− mice and that, hence, the expression of other products of Cpe-mediated cleavage (β-endorphin 1-26 (β-Ep ) and β-Ep 1-27 ) should similarly be increased. Further, we reasoned that if Cpe has a causal role in the observed phenotype, Cpe should be decreased by diet-induced obesity in WT, but not PomcFoxo1 −/− , mice, and the latter mice should be protected against weight gain. Likewise, Cpe gain of function should phenocopy FoxO1 ablation in Pomc neurons, and Pomc-Foxo1 −/− mice should be inured to the homeostatic changes brought about by calorie restriction.
Evidence of increased Cpe activity in Pomc-Foxo1 −/− mice Gene expression studies revealed that Cpe mRNA expression was increased in arcuate nucleus but not in paraventricular nucleus of Pomc-Foxo1 −/− mice (Fig. 3a,b) , consistent with a cell-autonomous effect of FoxO1 ablation.
Increased arcuate nucleus Cpe activity is expected to increase generation of carboxy-terminal cleavage products of β-Ep 1-31 , β-Ep 1-26 and β-Ep 1-27 . Indeed, HPLC elution profiles of mediobasal hypothalamus protein extracts showed lower amounts of β-Ep 1-31 and higher amounts of β-Ep 1-26 and β-Ep 1-27 in Pomc-Foxo1 −/− (g) NCD intake (24-h) in 15-week-old, body weight-matched male mice after intraperitoneal leptin injection. PBS was injected at day 0 (n = 4). (h) Serum leptin concentrations in male mice after 16-h fast, ad libitum feeding and 24-h fast followed by 6-h refeeding (n = 16-37). Data represent means ± s.e.m. *P < 0.05; **P ≤ 0.01; ***P ≤ 0.001 by unpaired t test. #P ≤ 0.05 by ANOVA.
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Metabolic correlates of Cpe loss-and gain-of-function
Given our hypothesis on the role of Cpe, we tested whether Cpe levels decline in diet-induced obesity and whether somatic deletion of FoxO1 in Pomc neurons can prevent the decline, protecting
Pomc-Foxo1 −/− mice from weight gain. Accordingly, we observed a 50% decrease in fasting Cpe mRNA in the arcuate nucleus of mice rendered obese by high-fat diet (HFD) (Fig. 4a) . In contrast, adult Pomc-Foxo1 −/− mice on a HFD were partly protected from weight gain (Fig. 4b,c) and showed a twofold rise in fasting Cpe levels in the arcuate nucleus (Fig. 4d) . These data are consistent with a To establish a causal link between Cpe and the phenotype of PomcFoxo1 −/− mice, we delivered adenovirus encoding Cpe to the arcuate nucleus of C57BL6 mice and analyzed feeding behavior. One week after adenoviral delivery, mediobasal hypothalamus Cpe expression was approximately twofold higher in mice that had received the Cpe adenovirus compared to GFP controls (Fig. 4e) . Post-surgical body weight and basal food intake did not differ between the two groups (data not shown). But mice overexpressing Cpe had lower refeeding response (Fig. 4f) and decreased nocturnal locomotor activity (Fig. 4g) , consistent with the hypothesis that elevated Cpe levels have anorexient effects.
Calorie restriction promotes physical activity in the short term, probably as a result of increased foraging behavior 37 . We reasoned that Pomc-Foxo1 −/− mice would be protected against this adaptive change. After a 6-d calorie restriction regimen (60-70% of ad libitum food intake), energy expenditure was similar in WT and Pomc-Foxo1 −/− mice (Fig. 4h) , but the latter mice failed to mount a foraging response (Fig. 4i) . Consequently, energy expenditure relative to locomotor activity dropped markedly in WT mice, reflecting increased energy efficiency, but not in mutant mice (Fig. 4j) . Notably, in the basal state, Pomc-Foxo1 −/− mice showed a trend toward increased serum ghrelin that also mimics calorie restriction (Supplementary Fig. 6c ), similar to results seen in a prior study in cattle 38 . These data support the hypothesis that Pomc-Foxo1 −/− mice are inured to behavioral changes associated with short-term calorie restriction.
-MSH inhibits hypothalamic Pcsk1
We also examined expression of Pcsk1 mRNA and protein in PomcFoxo1 −/− mice (Fig. 5a-d) . We detected a ~50% decrease that, unlike that of Cpe mRNA, was not confined to the arcuate nucleus, but was also seen in the paraventricular nucleus (Fig. 5b,c) , consistent with a paracrine effect of increased α-Msh. The decrease of Pcsk1 was unexpected, given that leptin sensitivity was increased (Fig. 2g) and that leptin increases Pcsk1 expression in hypothalamic neurons 15 . We therefore investigated whether the reduction of hypothalamic Pcsk1 results from feedback inhibition by α-Msh.
Intracerebroventricular injection of NDP-α-Msh reduced Pcsk1 levels in the the arcuate nucleus and paraventricular nucleus by ~50% (Fig. 5e,f) . Moreover, α-Msh suppressed Pcsk1 reporter gene activity by ~60% in Neuro2A cells (data not shown) and decreased endogenous Pcsk1 expression by ~50% in primary mediobasal hypothalamus cells (Fig. 5g) . These data indicate that there is feedback inhibition of hypothalamic Pcsk1 by α-Msh and suggest that reduced Pc-1 abundance in refed Pomc-Foxo1 −/− mice is the result of increased α-Msh expression.
FoxO1 inhibits Cpe expression independently of DNA binding
We wanted to determine whether FoxO1 regulates Cpe directly. ChIP assays showed occupancy of the Cpe promoter by FoxO1 in Neuro2A cells (Fig. 5h) . Moreover, constitutively nuclear FoxO1 (ref. 39) suppressed reporter gene activity driven by a Cpe promoter transfected in Neuro2A cells in a dose-dependent manner (Fig. 5i) . The promoter fragment contains two putative FoxO1 consensus-binding sites, but mutations of neither site, alone or in combination, affected the ability of FoxO1 to repress transcription (data not shown).
We then tested a DNA binding-deficient FoxO1 (ref. 40) and found that it also repressed Cpe promoter activity (Fig. 5j) , indicating that FoxO1 acts as a co-repressor of Cpe transcription independent of DNA binding. 
DISCUSSION
The key findings of this work are the demonstration that FoxO1 ablation in hypothalamic Pomc neurons reduces food intake without concurrently decreasing energy expenditure or leptin levels and the identification of a mechanism linking this phenotype to the obesity susceptibility gene Cpe. The uncoupling of hypophagia and reduced body weight from energy expenditure and leptin levels is, to our knowledge, unprecedented. The role of FoxO1 in the modulation of neuropeptide function by regulation of their post-translational processing is also new.
Multiple lines of evidence support the causal involvement of Cpe in the phenotype of Pomc-Foxo1 −/− mice, including arcuate nucleusrestricted increase of Cpe expression, protection from weight gain associated with reversal of diet-induced Cpe suppression, ability of Cpe gain of function in the arcuate nucleus to phenocopy key features of the FoxO1 loss of function, lack of foraging behavior in calorierestricted Pomc-Foxo1 −/− mice and repression of Cpe promoter activity by FoxO1. Moreover, neuropeptide patterns in Pomc-Foxo1 −/− mice (increased α-Msh, β-Ep 1-26 , and β-Ep 1-27 expression) are opposite to those seen in Cpe-deficient mice (decreased α-Msh, low β-Ep 1-27 , absent β-Ep 1-26 , and elevated β-Ep 1-31 expression) 34 . β-Ep 1-26 and β-Ep 1-27 have markedly reduced opiatergic activity 41, 42 .
The dissociation of food intake from energy expenditure in Pomc-Foxo1 −/− mice invites a comparison with the phenotype of transgenic mice overexpressing the deacetylase sirtuin-1, whose substrates include FoxO1. In these mice, decreased food intake fails to affect body weight, owing to decreased locomotor activity 43 . The two models are quite different in design, because the sirtuin-1 gain of function is generalized, and thus the effects cannot be ascribed precisely to any one tissue or cell type. Despite this caveat, it is notable that changes in energy homeostasis are opposite in the two models, consistent with the notion that a gain of sirtuin-1 function would promote FoxO1 activity via deacetylation 44 and, thus, with a specific role of sirtuin-1 and FoxO1 in linking food intake with energy expenditure.
The decrease in Agrp expression in Pomc-Foxo1 −/− mice is likely to be secondary to increased leptin expression. The association of leanness, hyperleptinemia and increased leptin sensitivity has been observed in mice with neuronal ablation of tyrosine phosphatase PTP-1B, possibly as a result of increased leptin receptor signaling 45 . But unlike neuron-specific Ptp1b −/− mice, Pomc-Foxo1 −/− mice have normal energy balance and insulin sensitivity.
The relatively higher lean mass observed in Pomc-Foxo1 −/− mice is reminiscent of the preservation of muscle mass observed in calorierestricted mice carrying a signal transducer and activator of signaling-3 signaling-incompetent leptin receptor 32 and ostensibly indicates that hypothalamic FoxO1 inactivation is conducive to preservation of muscle mass during calorie restriction.
In addition to elucidating the relationship between Cpe and FoxO1, the phenotype of Pomc-Foxo1 −/− mice uncovered a new regulatory loop for neuropeptide processing. Pcsk1 is nutritionally regulated: leptin increases Pcsk1 expression, whereas fasting decreases it 13, 15, 16 . But the fasting signal required to suppress Pcsk1 was hitherto unknown. The decreased amount of hypothalamic Pc-1 in Pomc-Foxo1 −/− mice, despite their heightened leptin sensitivity, suggested to us a potential link between elevated α-Msh and low Pc-1 expression. In Figure 5a -g, we provide in vitro and in vivo evidence to support the conclusion that α-Msh is the fasting signal that inhibits Pcsk1. This interpretation can explain the paradoxical increase of Pc-1 activity seen in the paraventricular nucleus of ob/ob mice with decreased hypothalamic α-Msh expression 46 .
In conclusion, we show that the obesity susceptibility gene Cpe is regulated by FoxO1 in the hypothalamus to link food intake with energy expenditure. Furthermore, the decrease of Cpe levels in diet-induced insulin resistance adds a potential new dimension to the understanding of the mechanisms of this common metabolic abnormality. Namely, it can be envisioned that central insulin resistance leads to increased FoxO1 activity and inhibition of Cpe, resulting in impaired Pomc processing, which, in turn, promotes food intake and leads to further insulin resistance, setting off a self-perpetuating cycle. However, the separation of the weight-reducing from the energy expenditure effects in Pomc-Foxo1 −/− mice is noteworthy, and it suggests that Cpe stimulation can circumvent the primary adaptation associated with weight reduction, namely the increase in energy efficiency that predisposes to weight regain 47 . Hence, Cpe may prove an attractive candidate for drug development in the treatment of obesity and insulin resistance.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/. 
ONLINE METHODS
Mice. C57BL/6 and Gt(ROSA)26Sor tm2Sho mice were from Jackson Laboratories. The Columbia University Animal Care and Utilization Committee approved all procedures. NCD had 62.1% calories from carbohydrates, 24.6% from protein and 13.2% from fat (PicoLab rodent diet 20, 5053; Purina Mills); HFD had 20% calories from carbohydrates, 20% from protein and 60% from fat (D12492; Research Diets). We measured weight and length to calculate body mass index and estimated body composition by nuclear magnetic resonance (Bruker Optics). We generated Pomc-specific FoxO1 knockouts by mating Pomc-Cre-transgenic mice 30 with Foxo1 flox/flox mice 48 and genotyped them as previously described 49 . We excluded from analyses Pomc-Foxo1 −/− mice that showed widespread recombination owing to stochastic embryonic expression of Pomc-Cre (~5%).
Restraint stress. We handled mice as previously described to habituate them 49 and drew blood for basal corticosterone from the tail vein during the first 3 h of light. We restrained mice using a 3-cm-wide plastic cylinder (Falcon).
Metabolic analyses. We measured food intake with feeding racks (Firma Wenzel). For refeeding experiments, we habituated mice to feeding racks for 3 d, fasted them for 18 h, placed feeding racks 2 h after the start of the light phase and measured food intake for 6 h thereafter. We used a TSE Labmaster Platform (TSE Systems) for indirect calorimetry and activity measurements 43 . For calorie restriction experiments, we housed 8-week-old male mice on NCD in calorimetry chambers for 1 week for baseline recordings, after which we provided 60% of ad libitum food intake for 3 d (initiation period), followed by 3 d of 70% ad libitum intake (stabilization period) in two daily doses. We examined leptin sensitivity in 15-week-old, weight-matched male mice. After habituation (twice daily PBS injection), we injected leptin (2 mg per kg body weight twice daily for 3 d) and measured body weight and food intake. We used ELISA for leptin (Millipore), corticosterone (Assay Designs) and ghrelin (RayBiotech) (measured 1 h before the dark phase).
Stereotactic injections.
We performed stereotactic manipulations in 15-week-old male C57BL/6 mice 50 . We injected [Nle 4 , D-Phe 7 ] (NDP)-α-Msh (1 nmol in 2 µl saline) (Phoenix Pharmaceuticals) or saline in the left brain ventricle (−0.2 mm anterior and 1.0 mm lateral to bregma and 2.3 mm below the skull surface). We killed the mice after 5 h and collected the arcuate nucleus and paraventricular nucleus using micropunches. We verified correct positioning of intracerebroventricular cannulae by injecting methylene blue (1%) after killing. To deliver AdV-Cpe or AdV-GFP to the arcuate nucleus, we injected 0.3 µl of purified virus (1 × 10 12 plaque-forming units per ml) 51 −1.5 mm anterior and 0.5 mm lateral to bregma and 5.3 mm below the skull surface 9 . After 1 week, we performed fasting and refeeding experiments.
Immunostaining and fluorescence in situ hybridization. We perfused mice with saline and then formalin (for immunostaining) or 4% paraformaldehyde (for fluorescence in situ hybridization). We froze brains in OCT (Sakura, CA, USA), and cut 30-µm-thick coronal sections for GFP-specific immunohistochemistry (Molecular Probes/Invitrogen), or serial 10-µm-thick coronal sections (bregma −0.8 mm to −2.4 mm) for fluorescence in situ hybridization with Pomc and Npy riboprobes, using tyramide amplification reagents (PerkinElmer) and nuclear staining with Hoechst 33342 (Molecular Probes/Invitrogen). We acquired images to count neurons 49 .
RNA procedures. We extracted RNA with Trizol (Invitrogen) and performed quantitative PCR using LightCycler 1.5 Carousell and LightCycler FastStart DNA Master PLUS SYBR Green I (Roche). Primer sequences are available upon request.
Western blotting. We used T-PER Tissue Protein Extraction Reagent (Pierce) supplemented with protease and phosphatase inhibitors (Roche) to isolate proteins and blotted with antibodies to the following proteins: Pc-1 (sc-33813; Santa Cruz Biotechnology), Pc-2 (P9007-87; United States Biologicals), β-actin (CP01; Calbiochem) and Cpe (SC34321; Santa Cruz Biotechnology).
Chromatin immunoprecipitation assays. We isolated intact chromatin and immunoprecipitated FoxO1 as previously described 9 and used primers 5′-TGGCTTCTAGCCAGACCTTG-3′ (−442 to −422) and 5′-GCCAGGG ATGTTGGGTTTAT-3′ (−148 to −136) to amplify the Cpe promoter.
Hypothalamic neuropeptide assays and reverse-phase high-performance liquid chromatography. We extracted mediobasal hypothalamus in 0.1N HCl 52 . We measured Pomc precursor by enzyme immunoassay 53 , β-endorphin and α-Msh by radioimmunoassay 52 , Acth by radioimmunoassay with antiserum against Acth 7-18 , (IgG Corporation) 54 and Agrp by sandwich ELISA (R&D Systems). We performed HPLC as previously described 55 .
Transfection and promoter studies. We performed luciferase assays in Neuro2A cells transfected with WT, constitutively nuclear or constitutively nuclear, DNA binding-deficient FoxO1 40 as previously described 15 , using α-Msh (Sigma-Aldrich) (1 × 10 −6 M). We collected and cultured primary cells from pooled hypothalami of 7-d-old Pomc-Gfp) mice (n = 6), using Papain Dissociation System (Worthington Biochemical) as previously described 9 .
Statistical analyses. We analyzed data with Student's t test or repeated-measures ANOVA. P values below 0.05 were considered statistically significant.
